Vanberbilt Biomarker Developmental Laboratory

范伯比尔特生物标志物发育实验室

基本信息

批准号：
8720716
负责人：
Daniel C Liebler
金额：
$ 61.53万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-08-20 至 2015-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8720716
关键词：
Address Algorithmic Software Biological Biological Assay Biological Markers Blood Cancer Center Characteristics Clinical Collection Colorectal Cancer Complex Coupled Data Set Detection Development Diagnosis Diagnostic tests Disease Early Detection Research Network Early Diagnosis Equipment and supply inventories Experimental Designs Funding Genomics Goals Informatics Institutes Laboratories Learning Link Liquid Chromatography Malignant Neoplasms Malignant neoplasm of lung Mass Spectrum Analysis Methods Mutation Normal tissue morphology Pathway Analysis Peptides Performance Phase Phenotype Plasma Post-Translational Protein Processing Process Proteins Proteome Proteomics Research Infrastructure Resected Resources Screening for cancer Shotguns Signal Transduction Source Specimen Technology Technology Assessment Thoracic Oncology Tissues Tumor Tissue Validation Variant Work base colorectal cancer screening instrumentation multiple reaction monitoring mutant novel oncology program programs tandem mass spectrometry tool tumor

项目摘要

DESCRIPTION (provided by applicant): This application proposes a Vanderbilt Biomarker Developmental Laboratory (Vanderbilt BDL), which will serve as a component of the NCI Early Detection Research Network (EDRN). The Vanderbilt BDL will be established within the Jim Ayers Institute for Precancer Detection and Diagnosis in the Vanderbilt-lngram Cancer Center which provides outstanding resources, instrumentation and staff dedicated to the problem of biomarker development. The Vanderbilt BDL will employ standardized liquid chromatography-tandem mass spectrometry (LC-MS/MS) and liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) analysis platforms for unbiased discovery and targeted quantitation of protein biomarkers. These analysis platforms are coupled to extensive informatics support infrastructure and ongoing biospecimen collections of the Ayers Institute and the Thoracic Oncology Program in the Vanderbilt-lngram Cancer Center. The Vanderbilt BDL will address the goals of the EDRN BDL program through three specific aims, 1) Develop and apply new informatics tools and approaches to identify mutant, variant and modified proteins as candidate cancer biomarkers. This work will emphasize application of new sequence tagging and signal analysis algorithms and software to identify novel protein forms that distinguish cancer phenotypes, 2) Discover and verify protein biomarker candidates for plasma-based detection of colorectal and lung cancers. This work will apply standardized shotgun proteomics analyses for biomarker candidate discovery in tissues and a standardized LC- MRM-MS platform for quantitation of biomarker candidates in plasma. The Vanderbilt BDL will interact closely with a proposed EDRN Biomarker Reference Laboratory (William Pao, PI) and a proposed EDRN Clinical Validation Center (Pierre Massion, PI) at Vanderbilt as well as with EDRN network partners to broadly deploy standardized proteomic technologies for biomarker development.

描述（由申请人提供）：本申请提出了Vanderbilt生物标志物发展实验室（Vanderbilt BDL），该实验室将作为NCI早期检测研究网络（EDRN）的组成部分。 Vanderbilt BDL将在吉姆·艾尔斯（Jim Ayers）在vanderbilt-lngram癌症中心的吉姆·艾尔斯（Jim Ayers）预测和诊断研究所内建立，该中心提供了出色的资源，仪器和专门针对生物标志物发展问题的员工。 Vanderbilt BDL将采用标准的液相色谱串联质谱法（LC-MS/MS）和液相色谱 - 形成 - 形成反应监测质谱质谱法（LC-MRM-MS）分析平台，以无偏见的发现和靶向蛋白质生物标志物的靶向定量。这些分析平台与Ayers Institute的广泛信息学支持基础架构和持续的生物传播集合以及范德比尔特Lngram癌症中心的胸腔肿瘤学计划。 Vanderbilt BDL将通过三个特定目标解决EDRN BDL计划的目标：1）开发和应用新的信息学工具和方法，以识别突变体，变体和改良的蛋白质作为候选癌症生物标志物。这项工作将强调使用新的序列标记和信号分析算法和软件来识别区分癌症表型的新型蛋白质形式，2）发现和验证蛋白质生物标志物候选物，用于基于血浆的结直肠癌和肺癌的检测。这项工作将应用标准化的shot弹枪蛋白质组学分析，以在组织中的生物标志物候选候选和标准化的LC-MRM-MS平台进行定量血浆中的生物标志物候选者。 Vanderbilt BDL将与拟议的EDRN生物标志物参考实验室（William Pao，PI）和Vanderbilt的EDRN临床验证中心（Pierre Massion，PI）以及EDRN网络合作伙伴以及以广泛部署生物标志物开发的标准化蛋白质组学技术的相互作用。